At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
Alpha-Gal Glycosphingolipidbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study To Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection Of Alpha-Gal Glycosphingolipids In Patients With Advanced Or Refractory Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Alpha-Gal Glycosphingolipid for Neoplasm Metastases. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral injection (Glycosphingolipids) GSL alpha-GAL (beta-galactosidase) in patients with advanced, refractory solid tumors who have failed standard therapies or are not eligible for standard treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm Metastases
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedApr 2008
Primary CompletionJul 2011
TodayJul 2026
First PostedApr 29, 2008
Enrollment StartJul 1, 2007
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.2 years ago
Interventions
Alpha-Gal Glycosphingolipidbiological
Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity